JP7131772B2 - 熱安定性ｆｇｆ２ポリペプチド及びその使用 - Google Patents

熱安定性ｆｇｆ２ポリペプチド及びその使用 Download PDF

Info

Publication number
JP7131772B2
JP7131772B2 JP2018546742A JP2018546742A JP7131772B2 JP 7131772 B2 JP7131772 B2 JP 7131772B2 JP 2018546742 A JP2018546742 A JP 2018546742A JP 2018546742 A JP2018546742 A JP 2018546742A JP 7131772 B2 JP7131772 B2 JP 7131772B2
Authority
JP
Japan
Prior art keywords
fgf2
polypeptide
cells
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018546742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500414A5 (enExample
JP2019500414A (ja
Inventor
ドヴォラク，ペトル
クレイチー，パヴェル
バレク，ルカス
エイセレオヴァ，リヴィア
コネチュナー，ザネタ
ドヴォラク，パヴェル
ベドナーシュ，ダヴィト
ブレゾフスキー，ヤン
セバストヴァ，エヴァ
ハロウプコヴァー，ラトカ
シュチェパーンコヴァー，ヴェロニカ
ヴァナチェク，パヴェル
プロコプ，ズビニェク
ダムボルスキー，イリ
ボサコヴァー，ミハエラ
Original Assignee
マサリコヴァ ウニヴェルジタ
エナンティス スポレチノスト エス ルチェニム オメゼニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マサリコヴァ ウニヴェルジタ, エナンティス スポレチノスト エス ルチェニム オメゼニム filed Critical マサリコヴァ ウニヴェルジタ
Publication of JP2019500414A publication Critical patent/JP2019500414A/ja
Publication of JP2019500414A5 publication Critical patent/JP2019500414A5/ja
Application granted granted Critical
Publication of JP7131772B2 publication Critical patent/JP7131772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2018546742A 2015-11-27 2016-10-03 熱安定性ｆｇｆ２ポリペプチド及びその使用 Active JP7131772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802.1 2015-11-27
EP15196802 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (3)

Publication Number Publication Date
JP2019500414A JP2019500414A (ja) 2019-01-10
JP2019500414A5 JP2019500414A5 (enExample) 2019-12-05
JP7131772B2 true JP7131772B2 (ja) 2022-09-06

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546742A Active JP7131772B2 (ja) 2015-11-27 2016-10-03 熱安定性ｆｇｆ２ポリペプチド及びその使用

Country Status (12)

Country Link
US (1) US11746135B2 (enExample)
EP (1) EP3380508B1 (enExample)
JP (1) JP7131772B2 (enExample)
KR (1) KR102650035B1 (enExample)
CN (1) CN108779158B (enExample)
AU (1) AU2016359722B2 (enExample)
CA (1) CA3006388C (enExample)
ES (1) ES2824479T3 (enExample)
LT (1) LT3380508T (enExample)
PL (1) PL3380508T3 (enExample)
SG (1) SG11201804402WA (enExample)
WO (1) WO2017089016A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531B (zh) * 2019-06-19 2022-11-01 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
CN115103903A (zh) * 2019-09-19 2022-09-23 西北大学 用于人诱导型多能干细胞的具成本效益的培养基和操作方案
US12103953B2 (en) 2019-11-25 2024-10-01 Korea Institute Of Ocean Science Technology FGF2 polypeptide with improved temperature stability and protease resistance and use thereof
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
WO2024110932A1 (en) * 2022-11-25 2024-05-30 Btl Healthcare Technologies A.S. The fgf-2 polypeptides with improved stability, the process for preparing the fgf-2 polypeptides and use thereof
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
KR102988516B1 (ko) * 2023-06-02 2026-07-09 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
KR102988515B1 (ko) * 2023-06-02 2026-07-10 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources
WO2026093988A1 (en) * 2024-11-01 2026-05-07 Btl Healthcare Technologies A.S. The fgf-2 polypeptides with improved thermal and oxidative stability, the process for preparing the fgf-2 polypeptides and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069298A1 (en) 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US20110053841A1 (en) 2006-09-28 2011-03-03 Avner Yayon N-terminal fgf variants having increased receptor selectivity and uses thereof
US20130236959A1 (en) 2011-12-16 2013-09-12 Guokai Chen Fgf-2 having enhanced stability
JP2014507951A (ja) 2011-03-01 2014-04-03 ヒューマンザイム インコーポレーテッド 線維芽細胞増殖因子の熱安定性変異体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
CA2172137C (en) * 1993-09-24 1999-12-14 Andrew Peter Seddon Surface loop structural analogues of fibroblast growth factors
AU6339198A (en) * 1997-02-26 1998-09-18 Ciblex Corporation Inhibitors of leaderless protein export
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7816140B2 (en) 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
WO2013082196A1 (en) 2011-11-28 2013-06-06 The Regents Of The University Of California bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF
WO2013090911A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins
US9474785B2 (en) * 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181B1 (en) 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069298A1 (en) 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US20110053841A1 (en) 2006-09-28 2011-03-03 Avner Yayon N-terminal fgf variants having increased receptor selectivity and uses thereof
JP2014507951A (ja) 2011-03-01 2014-04-03 ヒューマンザイム インコーポレーテッド 線維芽細胞増殖因子の熱安定性変異体
US20130236959A1 (en) 2011-12-16 2013-09-12 Guokai Chen Fgf-2 having enhanced stability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Cell Science，1999年，Vol.112，pp.2597-2606
The Journal of Biological Chemistry，2012年，Vol.287, No.5，pp. 3067-3078

Also Published As

Publication number Publication date
EP3380508B1 (en) 2020-07-22
CA3006388C (en) 2023-05-09
US20200270320A1 (en) 2020-08-27
EP3380508A1 (en) 2018-10-03
LT3380508T (lt) 2020-11-10
KR102650035B1 (ko) 2024-03-20
ES2824479T3 (es) 2021-05-12
BR112018010676A2 (pt) 2019-04-09
PL3380508T3 (pl) 2021-07-12
JP2019500414A (ja) 2019-01-10
WO2017089016A1 (en) 2017-06-01
CN108779158A (zh) 2018-11-09
CN108779158B (zh) 2026-05-01
US11746135B2 (en) 2023-09-05
SG11201804402WA (en) 2018-06-28
CA3006388A1 (en) 2017-06-01
AU2016359722B2 (en) 2020-09-17
KR20180080335A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
US11746135B2 (en) Thermostable FGF2 polypeptide, use thereof
AU2016359722A1 (en) Thermostable FGF2 polypeptide, use thereof
EP2401293B1 (en) Designer ligands of tgf-beta superfamily
CN111454350B (zh) 一种重组纤连蛋白突变体及其应用
Minchiotti et al. Structure-function analysis of the EGF-CFC family member Cripto identifies residues essential for nodal signalling
CN116589560B (zh) 生物合成重组人源化纤连蛋白以及制备方法
JP7838126B2 (ja) 生合成による人体構造性材料の製造方法
Garcia Garcia et al. Alteration of microstructure in biopolymeric hydrogels via compositional modification of resilin-like polypeptides
WO2025148254A1 (zh) 生物合成人体结构性材料xvii型胶原蛋白的方法
JP2014100141A (ja) 多能性幹細胞培養方法
CN105176908B (zh) 一种重组人成纤维细胞生长因子(fgf)-18的生产方法
JP3395181B2 (ja) 造血幹細胞増加剤
Lukassen et al. Disulfide Bond Pattern of Transforming Growth Factor β‑Induced Protein
Song et al. High-efficiency production of bioactive recombinant human fibroblast growth factor 18 in Escherichia coli and its effects on hair follicle growth
BR112018010676B1 (pt) Polipeptídeo termoestável e meio de cultura
US12344666B2 (en) PDGF mutants and methods of use thereof
CN119661684B (zh) 一种高抗炎活性的脂联素突变体及其制备方法与应用
CN100432107C (zh) 具有促红细胞生长因子活性的蛋白质及其用途
KR20190025569A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드
Liu et al. Computer-assisted engineering of stable human leukemia inhibitory factor
CZ309550B6 (cs) Termostabilní polypeptid na bázi FGF18 a jeho použití
HK40125817B (en) Recombinant humanized type viii collagen and use thereof
Shah Towards a structural understanding of the iRhom/ADAM17 complex
US20190135884A1 (en) Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof
KR20250110924A (ko) 개선된 안정성을 갖는 fgf-2 폴리펩티드, fgf-2 폴리펩티드를 제조하는 방법 및 그의 용도

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220817

R150 Certificate of patent or registration of utility model

Ref document number: 7131772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250